These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21266847)

  • 1. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity.
    Farrance CE; Chichester JA; Musiychuk K; Shamloul M; Rhee A; Manceva SD; Jones RM; Mamedov T; Sharma S; Mett V; Streatfield SJ; Roeffen W; van de Vegte-Bolmer M; Sauerwein RW; Wu Y; Muratova O; Miller L; Duffy P; Sinden R; Yusibov V
    Hum Vaccin; 2011; 7 Suppl():191-8. PubMed ID: 21266847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum.
    Farrance CE; Rhee A; Jones RM; Musiychuk K; Shamloul M; Sharma S; Mett V; Chichester JA; Streatfield SJ; Roeffen W; van de Vegte-Bolmer M; Sauerwein RW; Tsuboi T; Muratova OV; Wu Y; Yusibov V
    Clin Vaccine Immunol; 2011 Aug; 18(8):1351-7. PubMed ID: 21715576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
    Mlambo G; Maciel J; Kumar N
    Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
    Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
    Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
    Coban C; Philipp MT; Purcell JE; Keister DB; Okulate M; Martin DS; Kumar N
    Infect Immun; 2004 Jan; 72(1):253-9. PubMed ID: 14688103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein.
    Beiss V; Spiegel H; Boes A; Kapelski S; Scheuermayer M; Edgue G; Sack M; Fendel R; Reimann A; Schillberg S; Pradel G; Fischer R
    Biotechnol Bioeng; 2015 Jul; 112(7):1297-305. PubMed ID: 25615702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.
    Stowers AW; Keister DB; Muratova O; Kaslow DC
    Infect Immun; 2000 Oct; 68(10):5530-8. PubMed ID: 10992450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus.
    Kaslow DC; Isaacs SN; Quakyi IA; Gwadz RW; Moss B; Keister DB
    Science; 1991 May; 252(5010):1310-3. PubMed ID: 1925544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
    Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
    Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
    Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
    Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
    Kumar R; Angov E; Kumar N
    Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.